Vyome (NASDAQ:HIND – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.06 million during the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%.
Vyome Trading Up 3.8%
Shares of NASDAQ HIND traded up $0.06 during midday trading on Thursday, hitting $1.63. The company’s stock had a trading volume of 6,462 shares, compared to its average volume of 12,975. Vyome has a 1 year low of $1.53 and a 1 year high of $5.88. The business’s fifty day simple moving average is $1.90 and its two-hundred day simple moving average is $2.20.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vyome in a report on Tuesday, October 27th. Chardan Capital began coverage on shares of Vyome in a report on Thursday, September 3rd. They issued a “buy” rating and a $3.50 price objective on the stock. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $3.50.
Read Our Latest Stock Analysis on HIND
About Vyome
Vyome Holdings, Inc. (NASDAQ:HIND) is a biotechnology company focused on developing therapies for inflammatory and infectious diseases of the skin. The company applies research in the skin microbiome and immune modulation to identify potential treatments for conditions that can be difficult to manage with existing therapies. Vyome’s development programs have included topical drug candidates for dermatological conditions such as acne vulgaris and atopic dermatitis. Its lead programs are intended to address underlying biological mechanisms, including harmful bacterial activity and inflammation, rather than relying solely on conventional broad-spectrum antimicrobial approaches.
Read More
- Five stocks we like better than Vyome
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Vyome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyome and related companies with MarketBeat.com's FREE daily email newsletter.
